SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-164542
Filing Date
2023-06-09
Accepted
2023-06-09 17:00:58
Documents
14
Period of Report
2023-06-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d620811d8k.htm   iXBRL 8-K 35007
2 EX-3.1 d620811dex31.htm EX-3.1 7065
  Complete submission text file 0001193125-23-164542.txt   209273

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fnch-20230608.xsd EX-101.SCH 3236
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fnch-20230608_def.xml EX-101.DEF 14564
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20230608_lab.xml EX-101.LAB 24069
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20230608_pre.xml EX-101.PRE 15500
8 EXTRACTED XBRL INSTANCE DOCUMENT d620811d8k_htm.xml XML 5110
Mailing Address 75 STATE STREET SUITE 100 BOSTON MA 02109
Business Address 75 STATE STREET SUITE 100 BOSTON MA 02109 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40227 | Film No.: 231006165
SIC: 2836 Biological Products, (No Diagnostic Substances)